Join the Finerenone group to help and get support from people like you.
Finerenone News
Kerendia Approved for Heart Failure With Left Ventricular Ejection Fraction ≥40 Percent
MONDAY, July 14, 2025 – Following priority review, the U.S. Food and Drug Administration approved Kerendia (finerenone) for the treatment of patients with heart failure with left ventricular...
U.S. FDA Approves Kerendia (finerenone) to Treat Patients with Heart Failure with Left Ventricular Ejection Fraction ≥40% Following Priority Review
WHIPPANY, N.J., July 14, 2025 – Bayer today announced that the U.S. Food and Drug Administration (FDA) approved Kerendia (finerenone) to treat patients with heart failure (HF) with left ventricular e...
Combo Drug Treatment More Effective For Kidney Disease in Type 2 Diabetics
MONDAY, June 9, 2025 — Prompt treatment with a drug combo can effectively manage chronic kidney disease in people with type 2 diabetes, a new clinical trial shows. Patients prescribed the combination ...
Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM
MONDAY, June 9, 2025 – For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio...
Event-Free Survival Extended With Long-Term Finerenone in Heart Failure
MONDAY, Sept. 30, 2024 – Long-term treatment with finerenone is estimated to extend event-free survival among people with heart failure with mildly reduced or preserved ejection fraction, according...
FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
WHIPPANY, N.J.-- July 9, 2021 (BUSINESS WIRE)-- Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal...
Further information
Related condition support groups
Chronic Kidney Disease, Heart Failure, Congestive Heart Failure